Aptose Biosciences Inc. (NASDAQ:APTO) Sees Significant Increase in Short Interest

Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) was the target of a significant growth in short interest in the month of December. As of December 15th, there was short interest totalling 187,800 shares, a growth of 84.5% from the November 30th total of 101,800 shares. Approximately 0.3% of the company’s shares are sold short. Based on an average trading volume of 6,130,000 shares, the days-to-cover ratio is presently 0.0 days.

Institutional Investors Weigh In On Aptose Biosciences

An institutional investor recently raised its position in Aptose Biosciences stock. Sigma Planning Corp increased its stake in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 71.3% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 401,750 shares of the biotechnology company’s stock after purchasing an additional 167,282 shares during the quarter. Sigma Planning Corp owned about 2.22% of Aptose Biosciences worth $165,000 at the end of the most recent quarter. 26.62% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on APTO. HC Wainwright reissued a “buy” rating and issued a $2.00 price objective on shares of Aptose Biosciences in a research note on Tuesday, December 10th. StockNews.com assumed coverage on shares of Aptose Biosciences in a research note on Monday, December 23rd. They issued a “hold” rating on the stock.

Aptose Biosciences Stock Performance

Shares of NASDAQ:APTO traded down $0.01 during trading on Friday, hitting $0.24. 2,424,998 shares of the stock were exchanged, compared to its average volume of 1,790,199. The company has a market capitalization of $14.50 million, a price-to-earnings ratio of -0.08 and a beta of 1.06. Aptose Biosciences has a 1-year low of $0.13 and a 1-year high of $2.68. The company’s fifty day simple moving average is $0.28 and its 200-day simple moving average is $0.45.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.